Gastrointestinal Cancer | Specialty

Marshall Addresses Sidedness Issue in Colorectal Cancer

April 13th 2017

John L. Marshall, MD, discusses the results of the CALGB 80405 trial and other ongoing efforts to determine the underlying molecular basis for the sidedness issue in colorectal cancer.

Expert Discusses Differences Between Early-Onset and Traditional CRC

April 11th 2017

Manish Shah, MD, discusses ongoing efforts to understand the distinction between early-onset CRC and traditional CRC.

Nivolumab Effective in Advanced Anal Cancer

April 10th 2017

According to findings from a single-arm phase II trial, treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in an overall response rate of 24.3% in previously treated patients with squamous cell carcinoma of the anal canal.

Dr. Shah on Indications of Early-Onset CRC

April 6th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses indications of early-onset colorectal cancer (CRC).

Dr. Abou-Alfa on Trial of MEK162 in Advanced Biliary Cancer

April 3rd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.

Dual HER2 Targeting Effective in Refractory mCRC Subset

April 2nd 2017

A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.

Dr. Ramanathan on Treatment Resistance in Pancreatic Cancer

March 29th 2017

Ramesh K. Ramanathan, MD, vice chair of research in the Department of Hematology/Oncology at Mayo Clinic, discusses why pancreatic cancer is resistant to several therapies, as well as the early, preclinical promise observed with immunotherapy.

Experts Raise Awareness for Colorectal Cancer

March 25th 2017

Dr. Hemphill on Molecular Profiling for Gastric Cancer Treatment

March 18th 2017

Brian Hemphill, MD, clinical oncologist, Tennessee Oncology, discusses molecular profiling for gastric cancer treatment.

Dr. Kennedy on Importance of SIRFLOX Study in Liver-Metastatic CRC

March 17th 2017

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the importance of the SIRFLOX trial, which explored the efficacy of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres as treatment for patients with liver-metastatic colorectal cancer (CRC) versus standard frontline chemotherapy.

Emerging Data Could Show True Benefit of Y-90 Radioembolization in Liver-Metastatic CRC

March 17th 2017

Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.

Sequencing, Patient Selection Among Challenges in GI Cancers

March 17th 2017

Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.

Dr. O'Neil on Stemness Inhibitors for CRC Treatment

March 17th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of Medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the potential for stemness inhibitors as a treatment for patients with metastatic colorectal cancer (mCRC).

Dr. Bendell on Exciting Advancements in the Field of HCC

March 16th 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses exciting research and advancements in the field of hepatocellular carcinoma.

Novel Approaches, Individualization Needed in mCRC

March 16th 2017

Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.

Immunotherapy, Emerging Agents Offer Hope in GI Cancers

March 16th 2017

Johanna Bendell, MD, discusses the promising impact of immunotherapy and other emerging agents in the field of gastrointestinal cancer.

Dr. Ahn on Neoadjuvant Treatments for Patients With Gastric Cancer

March 13th 2017

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.

Dr. Al-Batran on Future of Treatment in Gastric Cancer

March 11th 2017

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

FDA Review Continues for Pembrolizumab in MSI-H Cancer

March 10th 2017

A supplemental biologics license application for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high cancer remains under review by the FDA.

Expert Hopes Novel Approaches Improve Outlook in Pancreatic Cancer

March 7th 2017

Ramesh K. Ramanathan, MD, discusses emerging agents and the hurdles oncologists are facing in the field of pancreatic cancer.